Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
06/2003
06/05/2003WO2003045362A2 Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
06/05/2003WO2003045354A1 Micropherules containing a pleuromutilin derivative
06/05/2003WO2003045335A2 Stem cell screening and transplantation therapy for hiv infection
06/05/2003WO2003045328A2 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof
06/05/2003WO2003045319A2 Targeted therapeutics and uses thereof
06/05/2003WO2003045318A2 Manipulation of cytokine levels using cd83 gene products
06/05/2003WO2003045317A2 Therapeutic protein and treatments
06/05/2003WO2003045228A2 Methods for treating autoimmune disorders, and reagents related thereto
06/05/2003WO2003014094A3 Heterocyclic aryl sulphonamides
06/05/2003WO2003011266A3 Azalide antibiotic compositions
06/05/2003WO2003008430A3 Porphyrin derivatives for photodynamic therapy
06/05/2003WO2003004526A3 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines
06/05/2003WO2002102835A8 Novel antimicrobial compounds
06/05/2003WO2002070002A3 Methods for regulation of immune responses to conditions involving mediator-induced pathology
06/05/2003WO2002069949A3 Combination therapy for reduction of toxycity of chemotherapeutic agents
06/05/2003WO2002060485A3 Use of immunoregulatory antibodies in the treatment of neoplastic disorders
06/05/2003WO2002058712A3 Probiotic compounds derived from lactobacillus casei strain ke01
06/05/2003WO2002046230A3 G-protein coupled receptors
06/05/2003WO2002042330A3 Cystoskeleton-associated proteins
06/05/2003WO2001079540A3 Methods for measuring drug resistance
06/05/2003US20030105307 Streptococcus pneumoniale 37-kDa surface adhesion a protein
06/05/2003US20030105277 Tat transport proteins; antiproliferative agents; antitumor agents
06/05/2003US20030105165 Gap junctions and EDHF
06/05/2003US20030105158 Hydrates of a neuraminic acid compound and crystalline forms thereof
06/05/2003US20030105143 Bactericides, antiseptics, cosmetics, cleaning compounds, enhaned oil recovery, papermaking
06/05/2003US20030105122 Compounds for enhancing chemotherapy
06/05/2003US20030105110 Novel compounds
06/05/2003US20030105107 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
06/05/2003US20030105090 For therapy of cancer, diabetes
06/05/2003US20030105084 Compound which inhibit the release of inflammatory cytokines
06/05/2003US20030105069 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
06/05/2003US20030105066 For use in producing antiviral, antifungal and antibacterial medicaments
06/05/2003US20030105062 Anti-bacterial agents based upon oxoanion binding
06/05/2003US20030105060 Synthetic oligomannosides, preparation and uses thereof
06/05/2003US20030105052 Oligoribonucleotide derivatives for specific inhibition of gene expression
06/05/2003US20030105006 For therapy of bacterial infections
06/05/2003US20030104992 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration
06/05/2003US20030104975 Useful for identification of compounds that induce or inhibit the recruitment of the p160 family cofactors, especially TIF-2 and/ or SRCs cofactors (Translation initiation factor-2 and steroid receptor cofactors)
06/05/2003US20030104620 Expression vector for expression of heterologous polypeptides and amplification of cell viral resistance; viricides
06/05/2003US20030104581 Biosynthesis and recovery of viricides from prokaryotic cells
06/05/2003US20030104528 Lymphocytes; transcription factors; interferons
06/05/2003US20030104500 Enzymatic assays for screening anti-cancer agents
06/05/2003US20030104478 Screening modulators of g-protein activity: for use in treatment of nervous system disorders
06/05/2003US20030104400 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of infammatory, immunol;ogical and nervous system disorders
06/05/2003US20030104082 Microbe inhibitors comprising antimicrobial isolates, botanical extracts or phytochemicals; also Commiphora myrrha, Commiphora molmol, Commiphora erythraea, sequiterpenes, nutrient, a vitamin, or a vitamin B complex.
06/05/2003US20030104056 Delayed release anti-viral product, use and formulation thereof
06/05/2003US20030104053 Drug dispersed in a solid unitary matrix formed of poly(ethylene oxide) and hydroxypropyl methylcellulose.
06/05/2003US20030104050 Process for preparing quick dissolving, high loading ribavirin compositions
06/05/2003US20030104045 Novel therapeutic binding molecule complexes
06/05/2003US20030104010 Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
06/05/2003US20030103998 Treatment of HIV and other viral infections using combinatorial therapy
06/05/2003US20030103997 Can be used to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection
06/05/2003US20030103989 Immunising pregnant mammal with antigen by any two routes of administration selected from intramammary, intraperitoneal and intramuscular and immunising mammal with antigen by third administration route, all three routes being different
06/05/2003US20030103982 Therapeutic using a bispecific antibody
06/05/2003US20030103974 Administering an antibodies or enzyme inhibitor of prothrombinase; therapeutic treatment of bacterial and viral infections, allograft and xenograft rejection, cancer, glomerulonephritis, gastrointestinal disorders and fetal loss
06/05/2003US20030103969 Therapeutic treatment using an anti-CD14 antibody
06/05/2003US20030103937 Comprises interleukins for enhancing engraphment of bone marrow during transplantation; for treating allergies and blood disorders
06/05/2003US20030103912 Breaking, disrupting film in aqueous solution; preventioncoagulation
06/05/2003CA2468878A1 Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their productionor generation
06/05/2003CA2468400A1 Antibiotics ge 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof
06/05/2003CA2468253A1 Process for coating a surface of a stent
06/05/2003CA2468159A1 4-aminoquinoline compounds
06/05/2003CA2468071A1 Triazolo[4,3-a]pyrido[2,3-d]pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof
06/05/2003CA2468020A1 Osteopontin-related compositions and methods
06/05/2003CA2467677A1 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
06/05/2003CA2467664A1 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof
06/05/2003CA2467647A1 Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma
06/05/2003CA2467565A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
06/05/2003CA2467397A1 Flavivirus vaccine delivery system
06/05/2003CA2466870A1 Methods for treating autoimmune disorders, and reagents related thereto
06/05/2003CA2466845A1 Manipulation of cytokine levels using cd83 gene products
06/05/2003CA2465846A1 Targeted therapeutics and uses thereof
06/05/2003CA2465072A1 Treatment of micro-organism infection
06/05/2003CA2454397A1 Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the cns
06/04/2003EP1316609A1 Acetoacetyl-CoA thiolase and its use for identifying new fungicidal substances
06/04/2003EP1315965A2 Methods and compositions for in vitro targeting
06/04/2003EP1315840A2 Biopanning and rapid analysis of selective interactive ligands (brasil)
06/04/2003EP1315830A2 Compositions and methods for targeting peptides in humans in vivo
06/04/2003EP1315807A2 Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides
06/04/2003EP1315804A2 Novel mmp-2 derivatives for use as inhibitors of integrin alpha vbeta 3
06/04/2003EP1315800A2 Human proteases
06/04/2003EP1315758A2 Methods and reagents for protease inhibition
06/04/2003EP1315752A1 Modified proteins, isolated novel peptides, and uses thereof
06/04/2003EP1315736A2 Nucleoside derivatives for the treatment of hepatitis c
06/04/2003EP1315735A1 Phosphate derivatives as immunoregulatory agents
06/04/2003EP1315727A2 7-oxo pyridopyrimidines
06/04/2003EP1315726A1 7- oxo pyridopyrimidines as inhibitors of cellular proliferation
06/04/2003EP1315719A1 Multivalent neuraminidase inhibitor conjugates
06/04/2003EP1315704A1 2-guanidino-4-aryl-quinazoline
06/04/2003EP1315698A1 Pyrrolidines as inhibitors of neuraminidases
06/04/2003EP1315518A2 Vaccine against microbial pathogens
06/04/2003EP1315513A2 "pseudo"-native chemical ligation
06/04/2003EP1315512A2 Adenoviral targeting and manipulation of immune system response using targeting peptides
06/04/2003EP1315511A2 Synthetic erythropoiesis stimulating proteins
06/04/2003EP1315509A2 Treatment of drug resistant organisms with nitric oxide
06/04/2003EP1315507A2 Hpv-specific short-mers
06/04/2003EP1315502A1 Method for treating erectile dysfunction and increasing libido in men
06/04/2003EP1315501A1 Alpha v integrin receptor antagonists
06/04/2003EP1315496A2 The treatment of inflammatory disorders
06/04/2003EP1315487A2 Flavoring systems for pharmaceutical compositions and methods of making such compositions
1 ... 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 ... 1798